Reading CING? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CING free→Reading CING? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CING free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Risk is elevated, and the sector backdrop is a headwind, which may impact CING's performance compared to its peers. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $4.93. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.70x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
25 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.52 → $-0.59 (-14.2% / 30d). 1 raised, 1 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 126.8% above current price.
0 positive, 2 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$418.
How much price usually moves either way.
On a bad day, this stock has moved -$716.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,913.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth speeds up, it could signal a positive shift in the company's performance.
Confirms:Cingulate's revenue growth shows an increase back toward 10% year over year.
Disproves:Revenue growth continues to slow or remains below 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CING yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Regulation FD Disclosure. On June 2, 2026, Cingulate Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) for its New Drug Application for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (“ADHD”). A copy of the press release is attached hereto as Exhibit 99.1 . The information included in this
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CING Cingulate Inc | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Cingulate plans to promptly resubmit the New Drug Application for CTx-1301 to the FDA after addressing the issues raised in the CRL.
Newly stated in 2026-Q2. The FDA issued a Complete Response Letter for CTx-1301, identifying specific Chemistry, Manufacturing and Controls information requests. Cingulate plans to address these issues and resubmit promptly. No financial impact is directly tied to this priority yet, but regulatory approval is critical for future revenue generation.
“The Company expects a prompt resubmission to FDA of the remaining requested information.”
Cingulate aims to manage its operating losses as it continues to develop its product pipeline.
Stated in 3 of last 3 quarters. Operating income was -$7.9M in 2026-Q1, compared to -$5.6M in 2025-Q4 and -$6.0M in 2025-Q3, indicating persistent operating losses. The trajectory shows limited progress in reducing losses, reflecting ongoing development costs.
“Operating income was -$7.9M, reflecting ongoing development costs.”
“Operating income was -$5.6M, indicating continued investment in development.”
“Operating income was -$6.0M, as development expenses persist.”
Cingulate plans to use the $12M raised from private placements to support its operations and strategic initiatives.
Newly stated in 2026-Q1. Cingulate raised approximately $12.0 million from private placements to support its operations and strategic initiatives. This capital infusion is crucial for sustaining operations amid ongoing losses, but the impact on financial stability remains to be seen.
“The aggregate gross proceeds from the Private Placement totaled approximately $12.0 million.”
Other Events. On June 2, 2026, the Company announced that the FDA has issued a CRL for its New Drug Application for CTx-1301. The FDA identified specific Chemistry, Manufacturing and Controls information requests in the CRL and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301. The Company expects a prompt resubmission to FDA of the remaining requested information addressing issues raised in the CRL.
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The current Class II directors of the Board of Directors (the “ Board ”) of Cingulate Inc. (the “ Company ”), Jeff Ervin and Jay Roberts, will not seek re-election when their respective terms expire at the Company’s 2026 Annual Meeting of Stockholders in an effort to reduce the size of the Board. On the date of the Annual Meeting, the Board intends…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 27, 2026, following stockholder approval of the Issuance Proposal (defined below), Zhanpeng “Frederick” Jiang was appointed as a member of the Board of Directors (the “ Board ”) of Cingulate Inc. (the “ Company ”), effective immediately, to serve as a Class I director until the Company’s 2028 Annual Meeting of Stockholders and until his su…